INMB Profile
INmune Bio, Inc. is a clinical-stage immunotherapy company dedicated to reprogramming the patient’s innate immune system for the treatment of cancer, Alzheimer’s disease, and non-alcoholic steatohepatitis. The company is actively engaged in developing and commercializing a range of innovative product candidates aimed at addressing hematologic malignancies, solid tumors, and chronic inflammatory conditions. By harnessing the power of the immune system, INmune Bio seeks to deliver transformative therapies that target some of the most challenging medical conditions.
Among its notable development programs, INKmune is designed to treat women with relapse-refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome. This therapy focuses on harnessing the body's innate immune response to combat these severe cancers. INB03 is another key program targeting advanced cancers characterized by elevated biomarkers of inflammation in the blood, aiming to provide new treatment options for patients with inflammatory cancer profiles. Additionally, XPro1595 is in development for Alzheimer’s disease, addressing the need for novel therapeutic approaches to this debilitating neurological condition.
INmune Bio is also advancing LivNate, a therapy for non-alcoholic steatohepatitis (NASH), a chronic liver disease associated with inflammation and liver damage. Quellor is another promising therapy under development for managing cytokine release syndrome and complications related to COVID-19, highlighting the company’s commitment to addressing urgent medical needs arising from the ongoing pandemic. These diverse programs reflect INmune Bio’s broad focus on leveraging immunotherapy to tackle a range of serious and unmet medical needs.
Founded in 2015 and headquartered in Boca Raton, Florida, INmune Bio has established strategic license agreements with notable partners including Xencor, Inc.; Immune Ventures, LLC; the University of Pittsburgh; and University College London. These collaborations enhance the company’s research capabilities and facilitate the advancement of its therapeutic candidates. With a strong foundation in innovative immunotherapy research and development, INmune Bio is positioned to make significant contributions to the treatment landscape for cancer,
|
